If Washington is serious about lowering prescription drug prices and expanding access, quality medicines already available at lower prices should be at the center of the conversation.
Generics need to be first in the affordability conversation, and policy needs to make sure patients can benefit from the competition they create.
Generics already play an extraordinary role in American healthcare. The opportunity is to make sure patients receive the full benefit.
AAM’s 2026 Savings Report shows that generic and biosimilar medicines generated $496 Billion in healthcare system savings in 2025 and $3.6 trillion over the past decade. Generics represented 89% of prescriptions filled while accounting for only 11.6% of prescription drug spending.
Start with what already works.
Nearly every conversation about lowering prescription drug prices starts with finding a new solution.
Generics First starts with a proven solution already available.
Different barriers. The same consquence: Patients miss the lower prices competition can deliver.
Generic medicines are a proven solution for lowering prescription drug prices, expanding access and creating competition. But too often, policies and market incentives can stand between patients and the lower-priced medicines already available to them.